Patients may only receive retatrutide through: Approved clinical trials registered with the MHRA and listed on the ISRCTN or ClinicalTrials.gov registries The MHRA Early Access to Medicines Scheme (EAMS) or compassionate use programmes, which allow access to promising unlicensed medicines for patients with serious conditions where no adequate alternative exists however, no such route is currently in place for retatrutide , and patients should not assume access is available outside of a formal trial It is strongly advised that patients do not attempt to source retatrutide through unregulated online pharmacies or grey-market suppliers
Current program details live on Ro's official website and LifeMD's official website
Human research provides important controlled data, but it does not eliminate uncertainty
Smoothies the worst offender
Alcohol can worsen dehydration during hot weather, and some semaglutide side effects like dizziness and fatigue may intensify in the heat
A study published in Nature found that over four years, patients taking semaglutide lost an average of 10.2% of their body weight, whereas those on a placebo lost only 1.5%
